Peel Hunt reissued their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research note issued to investors on Thursday. Peel Hunt currently has a GBX 1,000 ($12.70) price objective on the stock.
Other research analysts have also recently issued research reports about the stock. Numis Securities Ltd restated a buy rating and set a GBX 933 ($11.85) price objective on shares of Clinigen Group PLC in a report on Tuesday, October 25th. Stifel Nicolaus restated a buy rating and set a GBX 800 ($10.16) price objective on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Finally, N+1 Singer restated a buy rating and set a GBX 800 ($10.16) price objective on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus target price of GBX 856.60 ($10.88).
Clinigen Group PLC (LON:CLIN) opened at 718.00 on Thursday. Clinigen Group PLC has a 1-year low of GBX 492.75 and a 1-year high of GBX 793.50. The firm’s market capitalization is GBX 826.38 billion. The company has a 50-day moving average of GBX 738.50 and a 200-day moving average of GBX 657.49.
TRADEMARK VIOLATION WARNING: “Clinigen Group PLC’s (CLIN) Buy Rating Reiterated at Peel Hunt” was posted by Mideast Time and is owned by of Mideast Time. If you are accessing this article on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The correct version of this article can be viewed at http://www.mideasttime.com/clinigen-group-plcs-clin-buy-rating-reiterated-at-peel-hunt/1438520.html.
The business also recently declared a dividend, which was paid on Friday, November 25th. Shareholders of record on Thursday, November 3rd were paid a GBX 2.70 ($0.03) dividend. The ex-dividend date was Thursday, November 3rd. This represents a yield of 0.38%. This is a positive change from Clinigen Group PLC’s previous dividend of $1.30.
In other news, insider John Bacon sold 200,000 shares of the business’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of GBX 717 ($9.11), for a total value of £1,434,000 ($1,821,877.78). Also, insider Shaun Edward Chilton sold 97,246 shares of the business’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of GBX 750 ($9.53), for a total transaction of £729,345 ($926,623.05).
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.